Loading stock data…
PLX
$1.98+0.02 (+1.02%)
After Hours$1.98+0.00 (+0.00%)· Last close Jun 9
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protalix BioTherapeutics, Inc. in the Healthcare sector is trading at $1.98 with a market capitalization of $158M. Wall Street consensus targets $11.00 (2 analysts), implying a +455.6% move over the next 12 months. The stock is currently 38% below its 52-week high of $3.19, remaining 8.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +455.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.98
Potential Upside
72.1%
Whystock Fair Value$3.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$11.00+455.6%
Range$10.00 – $12.00
Fundamentals
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Ele...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$157.92M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.32
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.81%
Volume
Today's trading volume
460,291
Recent News
3 Penny Stocks With Market Caps Larger Than $100M To Consider
The market has climbed 1.2% in the last 7 days and an impressive 29% over the past year, with earnings forecasted to grow by 17% annually. While penny stocks might seem like a relic from earlier market eras, they offer a unique opportunity for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. In this article, we explore several penny stocks that stand out as hidden gems with potential for impressive returns.
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
Protalix BioTherapeutics Inc (PLX) reports a profitable quarter with significant milestone achievements and reaffirms its 2026 revenue guidance.
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1762414&tp_key=330c698581 Summary Protalix BioTherapeutics reported a $25 million milestone payment from Chiesi due to European Commission a
April 2026 Penny Stocks With Promising Potential
The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.